Role of oxidative stress and serum lipid levels in stable chronic obstructive pulmonary disease. Issue 12 (December 2015)

• Record Type: Journal Article
• Authors: Can, Ummugulsum; Yerlikaya, Fatma Humeyra; Yosunkaya, Sebnem
• Is Part Of: Journal of the Chinese Medical Association. Volume 78:Issue 12(2015)
• Publication Date: 2015-12
• Subjects: chronic obstructive pulmonary disease -- ischemia‐modified albumin -- oxidative stress -- oxidized low‐density lipoprotein -- total oxidant status; Medicine -- Periodicals; 610.5
• DOI: 10.1016/j.jcma.2015.08.004
• Languages: English
• ISSNs: 1726-4901

Abstract

Abstract : Background : Chronic obstructive pulmonary disease (COPD) has been associated with increased oxidative stress or reduced antioxidant resources. The main goal of this study was to evaluate the levels of serum ischemia‐modified albumin (IMA), oxidized low‐density lipoprotein (ox‐LDL), total oxidant status (TOS), and total antioxidant status in patients with stable COPD, compared with a control group. Methods : This study was performed on 51 patients with stable COPD (42 men and 9 women; mean age 56.92 ± 3.0 years) and 45 healthy control participants (32 men and 13 women; 54.8 ± 3.8 years). The levels of serum lipids, IMA, total antioxidant status, TOS, and ox‐LDL were measured in all participants. Results : The levels of serum IMA, ox‐LDL, and TOS were significantly higher in patients with COPD than those in control individuals. There was no difference between the levels of serum total antioxidant status, triglycerides, total cholesterol, and low‐density lipoprotein cholesterol (LDL‐C) of patients with COPD and those of control individuals. Serum high‐density lipoprotein cholesterol levels were significantly lower in patients with COPD than in control individuals. Conclusion : Our study indicated that serum IMA, ox‐LDL, and TOS may be increased as a result of chronic hypoxia, inflammation, and oxidative stress in patients with severe and very severe stable COPD. Our findings also revealed that IMA is higher in patients with Global Initiative for Chronic Obstructive Lung Disease Stages II, III, and IV, while TOS and ox‐LDL are higher in patients with Global Initiative for Chronic Obstructive Lung Disease Stage IV. Measurements of serum IMA, TOS, and ox‐LDL levels may be useful markers in the evaluation of stable COPD.